PRKCG and ocular melanoma: Further, N2a cells treated with 30% OM and V5-3 peptide (20 nM), a PKCγ antagonist29, for four days indicated that the increase of phosphorylated PKCγ induced by 30% OM was inhibited by V5-3 treatment (Fig. 3b).